---
schema_version: "secwatch.filing_event.v1"
accession: "0000856982-25-000045"
form_type: "8-K"
ticker: "MMSI"
cik: "0000856982"
company_name: "MERIT MEDICAL SYSTEMS INC"
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:23:35.201929+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merit Medical Q2 revenue up 13.2% to $382.5M; non-GAAP EPS $1.01, up 9.8%; appoints new CEO

## Summary
- Revenue $382.5M, +13.2% YoY; constant-currency revenue +12.5%, organic constant-currency +6.7%.
- GAAP EPS $0.54 (-11.6%), non-GAAP EPS $1.01 (+9.8%); GAAP operating margin 12.3% vs 13.6% prior year.
- Non-GAAP operating margin improved to 21.2% from 20.1%; free cash flow $89.1M in H1 2025, +8.1%.
- Acquired Biolife (StatSeal/WoundSeal hemostatic devices); no transaction value disclosed.
- Martha Aronson named President & CEO, effective Oct 3, 2025; Fred Lampropoulos becomes Chairman.

## SEC filing metadata
- accession: 0000856982-25-000045
- form_type: 8-K
- ticker: MMSI
- cik: 0000856982
- company_name: MERIT MEDICAL SYSTEMS INC
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/856982/000085698225000045/0000856982-25-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/856982/000085698225000045/mmsi-20250730x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000856982-25-000045
- JSON: https://secwatch.observer/filing/0000856982-25-000045.json
- Plain text: https://secwatch.observer/filing/0000856982-25-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.